Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active Surveillance

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorUniversity Hospital Tuebingen

About this trial

The study aims to show that treatment with LtAPD works better than a sham treatment or simply monitoring the condition closely without active treatment ("active surveillance"), in achieving complete healing of a tissue abnormality on the cervix called CIN 2, after 6 months. This will be confirmed by examining tissue samples under a microscope (histopathological examination).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female sex

Age 18 - 40 years at the time of signing the informed consent

Histologically confirmed CIN 2

Full visibility of the entire transformation zone (Type 1 or Type 2) and entire lesion in colposcopy

Disqualifiers

Histologically confirmed CIN other than CIN 2, or indication of (micro-) invasive cervical disease

CIN lesions extending to the vaginal vault or suspicion of endocervical disease

Current pregnancy or planned pregnancy within the next 6 months

Presence of severe local inflammation or active infection

Trial design

Design model

Parallel

Treatments tested in this trial

  • Treatment with low-thermal argon plasma devitalization

    Device

    Single session of LtAPD treatment applied to the CIN2 lesion under colposcopic guidance; outpatient, no anesthesia required.

  • Sham treatment

    Device

    Single session of sham treatment (no argon gas delivery and plasma ignition; acoustic signal to maintain blinding) followed by active surveillance according to current clinical guidelines.

Treatment groups

264 Participants
are divided into 2 treatment groups
Group A: LtAPDExperimental treatment 1 intervention
Group B: ShamSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Histopathological remission of CIN 2

Percentage of patients with histopathologically confirmed remission of CIN 2 (absence of CIN 2 or higher grade lesion), assessed by cervical biopsy/histopathological evaluation

Time frame
at 6 months

Secondary outcomes

1

HPV remission rate

Percentage of patients with HPV remission, assessed by validated HPV testing and p16 immunohistochemistry

Time frame
at 6 months
2

Cytological remission of CIN

Percentage of patients with cytological remission, assessed by Papanicolaou (PAP) smear according to the Bethesda classification system

Time frame
at 6 months
3

Quality of life, comfort/ discomfort of the treatment procedure and sexual activity

Change from baseline in quality of life and sexual health at baseline and 6 months, assessed by the Freiburg Index of Patient Satisfaction (FIPS) and the Sexual Activity Questionnaire (SAQ)

Time frame
at baseline, intervention, 6 months
4

Correlation of electrosurgical unit (ESU) and video data with CIN remission and applied argon plasma

assessed by correlation of ESU and video data with CIN remission and applied argon plasma

Time frame
at 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.